

1 **Maternal synapsin 1 autoantibodies are associated with neurodevelopmental**
2 **delay**

3 Isabel Bünger,^{1-2†} Konstantin L. Makridis,^{3-6†} 7 Jakob Kreye,^{1-5,7} Marc Nikolaus,^{3-5,7}
4 Eva Sedlin,³⁻⁴ Tim Ullrich,³⁻⁴ Helle Foverskov Rasmussen,¹⁻² Dragomir Milovanovic,²
5 Christian Hoffmann,² Johannes Tromm,² Markus Höltje,⁸ Harald Prüss,^{1-2#} Angela M.
6 Kaindl^{3-6#}

7

8 ¹Charité – Universitätsmedizin Berlin, Department of Neurology and Experimental
9 Neurology, Berlin, Germany

10 ²German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

11 ³Charité – Universitätsmedizin Berlin, Department of Pediatric Neurology, Berlin,
12 Germany

13 ⁴Charité – Universitätsmedizin Berlin, Center for Chronically Sick Children, Berlin,
14 Germany

15 ⁵Charité – Universitätsmedizin Berlin, German Epilepsy Center for Children and
16 Adolescents, Berlin, Germany

17 ⁶Charité – Universitätsmedizin Berlin, Institute of Cell- and Neurobiology, Berlin,
18 Germany

19 ⁷Berlin Institute of Health (BIH), 10178, Berlin, Germany

20 ⁸Charité - Universitätsmedizin Berlin, Institute of Integrative Neuroanatomy, Berlin,
21 Germany

22 †These authors contributed equally to this work and share first authorship

23 #These authors contributed equally to this work and share last authorship

24

25 Running title: Maternal synapsin autoantibodies in children

26

27 **Corresponding author:** Prof. Dr. med Angela M. Kaindl, Pediatric Neurology,
28 Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin,
29 Germany. Tel: +49 30 450 566112. E-Mail: angela.kaindl@charite.de

30

31 **Key words:** Synapsin 1; antineuronal autoantibodies; transplacental transfer,
32 maternofetal autoimmunity; developmental delay, intellectual disability, epilepsy,
33 behavioral problems

- 1 **No. of figures/tables:** 3 / 1
- 2 **Title / Running title:** 80 / 45 characters
- 3 **Abstract:** 137 words
- 4 **Body of manuscript:** 1797 words
- 5

1 **Abstract**

2 Maternal autoantibodies can be transmitted diaplacentally, with potentially
3 deleterious effects on neurodevelopment. Synapsin 1 (SYN1) is a neuronal protein
4 that is important for synaptic communication and neuronal plasticity. While
5 monoallelic loss of function (LoF) variants in the *SYN1* gene result in X-linked
6 intellectual disability (ID), learning disabilities, epilepsy, behavioral problems, and
7 macrocephaly, the effect of SYN1 autoantibodies on neurodevelopment remains
8 unclear. We recruited a clinical cohort of 208 mothers and their children with
9 neurologic abnormalities and analyzed the role of maternal SYN1 autoantibodies. We
10 identified seropositivity in 9.6% of mothers, and seropositivity was associated with an
11 increased risk for ID and behavioral problems. Furthermore, children more frequently
12 had epilepsy, macrocephaly, and developmental delay, in line with the SYN1 LoF
13 phenotype. Whether SYN1 autoantibodies have a direct pathogenic effect on
14 neurodevelopment or serve as biomarkers requires functional experiments.

15

1 **Introduction**

2 Synapsin 1 (SYN1) is a neuronal phosphoprotein encoded by the *SYN1* gene and
3 plays an important role in neurotransmitter release and neuronal plasticity (1, 2).
4 Patients with loss of function (LoF) variants in the *SYN1* gene have been associated
5 with X-linked phenotypes consisting of epilepsy, learning difficulties, intellectual
6 disability (ID), macrocephaly, behavioral problems, and autism-spectrum disorders
7 (ASD) (MIM#300491, MIM#300115) (3-5).

8 In recent years, anti-neuronal autoantibodies have been increasingly described to
9 cause target-specific autoimmune neurologic disorders, in some cases matching the
10 clinical phenotypes of patient carrying genetic variants of these targets. For example,
11 both patients with variants in GABA_A receptor subunit genes and those with GABA_A
12 receptor autoantibodies display epilepsy as a common phenotype (6-8).
13 Autoantibodies are usually regarded as those generated within an individual;
14 however, they can also be transferred diaplacentally from mother to child (9). As the
15 blood brain barrier is not yet fully matured, these autoantibodies of maternal origin
16 can target the developing brain and thereby potentially affect neurodevelopment (9).
17 There is increasing evidence that maternal immune activation through autoantibodies
18 can influence the occurrence of neurodevelopmental disorders, such as ASD (9). In
19 addition, multiple murine models have demonstrated the direct deleterious effect of
20 various anti-neuronal autoantibodies in offspring through gestational transfer (10-13).

21 In previous studies, autoantibodies against SYN1 have been identified in patients
22 with neurologic and psychiatric disorders (14, 15). We have recently shown that
23 SYN1 autoantibodies in pregnant women are associated with abnormalities of fetal
24 development including intrauterine growth retardation (Preprint) (16). However, their
25 role in mothers of children with defined neurologic disorders has not been studied so

1 far. Thus, we assessed the prevalence of SYN1 autoantibodies in mothers of a
2 cohort of 208 pediatric patients with neurological disorders.

3

4 **Material and Methods**

5 Cell-based assay

6 Synapsin 1b (SYN1b) cell-based assay (CBA) was performed using human
7 embryonic kidney (HEK293T) cells which were transfected with human SYN1b.
8 Methanol-fixed cells were then incubated with sera diluted 1:300. IgG AF488-
9 antibody (Dianova, #109-545-003), commercial rabbit SYN1/SYN2 antibody
10 (Synaptic Systems, #106002) and anti-rabbit IgG AF594-antibody (Jackson IR, #111-
11 585-003) were used to detect IgG binding. Two independent investigators scored the
12 CBA using the following semi-quantitative score: 0, no binding; 1, unspecific signal
13 ('background'); 2, positive (intensive binding). Sera were tested on control cells
14 overexpressing the NR1 subunit of the N-methyl-D-aspartate receptor (NMDAR),
15 contactin-associated protein 2 (Caspr2), and SYN1 CBA-positive sera also on
16 untransfected control HEK293T cells to exclude non-specific binding (14, 16).

17

18 Enzyme-linked immunosorbent assay

19 For the ELISA, 200 ng of recombinant rat Syn1-His-EGFP (17) was diluted in PBS
20 and incubated overnight at 4 °C in 96-well high-binding plates. Serum (1:200 diluted
21 in PBS containing 1% BSA, 0.05% Tween) was incubated for one hour at room
22 temperature, on which HRP-coupled anti-human IgG antibody (Dianova, #109-035-
23 003) was added for an additional hour. Ultra TMB substrate solution was added, and
24 reaction terminated after one minute with H₂SO₄. Absorbance at 450 nm was
25 measured and corrected with controls (mean of wells without serum and reference
26 absorbance at 630 nm).

1 Western blot

2 SDS-Page and Western blotting were performed as described using cortices from
3 *Syn1/2/3* triple knockout (TKO) mice and wild type (WT) mice (14). Sera of CBA with
4 scores of 1-2 were diluted to 1:200 and used to incubate membranes. A rabbit
5 polyclonal SYN1/2 antibody (#106002) was used as positive control and a mouse
6 monoclonal antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH,
7 Merck Millipore, #MAB374) served as loading control.

8 Clinical data and statistical analysis

9 We studied a cohort of 208 mothers of pediatric patients with neurological disorders
10 treated at the Center for Chronically Sick Children, Charité – Universitätsmedizin
11 Berlin, Germany. Patient data were collected blinded to maternal antibody levels
12 using a standardized data collection sheet. Statistical analysis was performed using
13 R (RStudio version 4.2.1) and the packages *crosstable*, *UpSetR*, and *psych*.
14 Descriptive statistics were performed to calculate percentages and frequencies.
15 Differences in categorical variables are reported as odds ratio and 95% confidence
16 interval. P values were calculated using the Chi-square test and Fisher's Exact
17 Probability Test, as applicable. Test results with $p < 0.05$ were considered statistically
18 significant. The study was approved by the local ethics committee (approval no.
19 #EA2/220/20).

20

21 **Results**

22 We screened sera for SYN1 autoantibodies in 208 mothers to assess the relationship
23 with neurodevelopment in children. Due to the explorative approach, no exclusion
24 criteria were set. Mothers gave birth at an average age of 30.93 ± 5.81 years.
25 Children (male $n=134$, 64.1%) were 6.6 ± 4.14 years old at testing. Developmental
26 delay in the domains speech ($n=158$, 75.7%) and motor skills ($n=153$, 73.1%) were

1 the most common findings. Furthermore, 135 patients had intellectual disability
2 (64.4%), and 83 patients had epilepsy (39.9%) (**Figure 1**).

3 In a first step, the patients' mothers were screened using the previously described
4 CBA (14). We used a visual-scoring system for antibody binding in which scores of 2
5 were considered as positive (**Figure 2A**). Positive binding was identified in 20
6 mothers (9.6%). In 30 mothers, unspecific binding was detected while all
7 others(n=158) showed no binding (**Figure 2B**). We further analyzed the sera of
8 mothers with a SYN1 ELISA. Here, we found only a weak correlation between the
9 CBA and ELISA results ($r=0.29$, **Figure 2C**). Possibly, these differing results can be
10 explained by the binding of SYN1 autoantibodies to conformational epitopes that are
11 not detected by ELISA. Therefore, we performed Western blots using the sera and
12 cortex homogenates of wild-type and *Syn1* triple knockout mice. We detected IgG
13 binding to wild-type mouse brain homogenates in four of the 20 CBA-positive sera
14 (**Figure 2D**). The other sera did not show immunoreactive bands at the expected
15 molecular weight. These results point towards SYN1 IgG autoantibodies binding to
16 linear SYN1 epitopes in only a small group, whereas autoantibodies against
17 conformational synapsin epitopes predominate.

18 We further analyzed children of mothers with a positive CBA (**Table 1**). Most
19 commonly the children had ID (n=18, 90%), speech delay (n=17, 85%), motor delay
20 (n=17, 85%), and epilepsy (n=12, 60%). Seven patients had a developmental and
21 epileptic encephalopathy (DEE). Cranial MRI was performed in 15 patients, with
22 abnormalities detected in eight patients (53.3%, **Table 1**). Genetic testing was carried
23 out in 13 patients, with variants (n=7) and microdeletions (n=1) identified in eight
24 patients (61.5%). Of these seven variants, one was classified as pathogenic (14.3%),
25 three as probably pathogenic (42.9%), and three as variants of unclear significance

1 (42.9%). The four patients with IgG binding to wild-type mouse brain, showed no
2 striking phenotypic differences to patients without binding (**Table 1**).

3 We next analyzed the clinical data based on the results of the CBA. While there
4 was no association between CBA and age of mothers, age at birth or children's age,
5 we found an increased risk for specific phenotypes in patients of mothers with
6 positive CBA. A positive CBA was a significant risk factor in their children for the
7 presence of ID (OR: 5.46 [95% CI: 1.52 - 35.01], $p = .0134$) and behavioral problems
8 (2.71 [1.07 - 7.23], $p = .0328$). Furthermore, patients showed a tendency for the
9 presence of macrocephaly (3.11 [0.81 - 9.92], $p = .0785$), epilepsy (2.47 [0.98 - 6.59],
10 $p = .0536$), ASD (1.32 [0.36 - 3.89], $p = .7493$), microcephaly (1.40 [0.47 - 3.72], $p =$
11 $.5882$), and a developmental delay in the domains speech (1.89 [0.60 - 8.34], $p =$
12 $.4167$) and motor skills (2.17 [0.69 - 9.55], $p = .2223$) (**Figure 2A and B**).

13

14 **Discussion**

15 In this study, we recruited a clinical cohort of 208 mothers and their children and
16 analyzed the prevalence of maternal SYN1 autoantibodies and their association with
17 developmental phenotypes. SYN1 IgG autoantibodies were detected through CBA in
18 9.6% of mothers with neurologically sick children. Most of the SYN1 CBA positive
19 cases were negative on Western blots under denaturing conditions, suggesting a
20 conformational dependency of their target binding, as similarly observed in other
21 human anti-neuronal autoantibodies (18). In the study by Hölting et al. in a cohort of
22 patients with various psychiatric and neurological disorders and SYN1
23 autoantibodies, binding was detected in immunoblots in about half of all patients (14).
24 It is unclear whether in less denaturing conditions more SYN1 CBA positive cases
25 would be positive. As in this study, we found IgG binding in immunoblots of 263

1 pregnant women screened for synapsin I autoantibodies in only 22.9% and found no
2 correlation between ELISA and CBA antibody levels (16).

3 SYN1 is member of the family of synapsins, encoded by the three genes *SYN1*,
4 *SYN2*, and *SYN3* in humans. SYN1 regulates the trafficking of synaptic vesicles
5 between the readily releasable pool and reserve pool. Furthermore, Syn1 moderates
6 neuronal development through neurite outgrowth and synaptogenesis (2). *Syn1*
7 mutant mice have severe epilepsy with generalized seizures (19).

8 We recently reported on a cohort of 263 pregnant women with seropositivity for
9 SYN1 autoantibodies in 13.3%, matching the prevalence in this cohort (16).
10 Seropositivity was associated with abnormalities of fetal development including
11 intrauterine growth retardation. In this study of 208 children with various neurologic
12 disorders, a positive maternal CBA showed a strong association with ID and
13 behavioral problems, while there was and a trend towards other abnormalities such
14 as macrocephaly and epilepsy. This is intriguing given that patients with LoF variants
15 in *SYN1* display a similar phenotype with epilepsy, ID, ASD, macrocephaly, and
16 behavioral problems (3-5). The lack of a clear association to these phenotypes can
17 possibly be explained by the low statistical power of the study, requiring larger
18 cohorts. In addition, due to the monocentric design and subsequent selection bias,
19 multicenter studies need to be conducted to increase power.

20 When further analyzing the 20 CBA-positive patients seven had identified genetic
21 variants/microdeletions of which one was considered pathogenic and three as likely
22 pathogenic variants. This raises speculation as to whether genetic alterations in brain
23 proteins may lead to neoantigen formation and increased autoimmunity. It is unclear
24 whether maternal autoantibodies against SYN1 have a direct pathogenic effect on
25 fetal development or rather represent a clinical biomarker of neuronal cell damage. It
26 has been shown that SYN1 autoantibodies can reach the cytoplasmic site through

1 FcγII/III-mediated endocytosis and thereby replicating the molecular *SYN1* LoF
2 phenotype *in vitro* (20). Other experimental studies have demonstrated the direct
3 pathogenic effect of maternal antineuronal autoantibodies such as NMDAR, Caspr2,
4 and aquaporin-4 antibodies (10-13). Further, Caspr2 autoantibodies present during
5 pregnancy are associated with ID and developmental disorders (21). However,
6 functional studies on the effects of *SYN1* autoantibodies on neurodevelopment are
7 lacking and should be performed at molecular resolution using patient-derived
8 monoclonal antibodies (22).

9

10 Although this study has several limitations, due to the heterogeneity of the pediatric
11 cohort, it indicates a potential influence of maternal *SYN1* autoantibodies on
12 neurodevelopment. Further prospective studies are needed in which pregnant
13 women are tested for maternal autoantibodies and their child's development is
14 closely monitored. Although these results do not currently trigger any direct
15 therapeutic or diagnostic consequence, they could influence standard treatment of
16 pregnant women in the long term and possibly lead to new therapeutic approaches.

17

1 **Acknowledgements**

2 We thank Stefanie Bandura, Matthias Sillmann, Doreen Brandl, Antje Dräger, and
3 Monika Majer for excellent technical assistance and study nurse support. J.K. and
4 M.N. are participants in the Berlin Institute of Health (BIH)-Charité Junior Clinician
5 Scientist Program. This work was supported by grants from the German Research
6 Foundation (DFG) (grants FOR3004, PR1274/4-1, PR1274/5-1, PR1274/9-1), by the
7 Helmholtz Association (HIL-A03), the German Federal Ministry of Education and
8 Research (Connect-Generate 01GM1908D), the Einstein Stiftung Fellowship through
9 the Günter Endres Fond, and the Sonnenfeld-Stiftung.

10

11 **Author Contributions**

12 Conceptualization: A.K. and H.P.; Patient recruitment: I.B., K.M., T.U. and E.S., CBA
13 and ELISA testing: I.B., J.K., H.F.R., M.H., D.M. and J.T; Western blotting: M.H.;
14 Data collection, analysis, and visualization: I.B. and K.L.M.; Resources: A.K. and
15 H.P.; Writing – original draft: I.B., K.L.M. Writing – review & editing: all authors.

16

17 **Conflicts of Interest**

18 Nothing to report.

19

20

1 **References**

- 2 1. Hilfiker S, Benfenati F, Doussau F, Nairn AC, Czernik AJ, Augustine GJ, et al.
3 Structural Domains Involved in the Regulation of Transmitter Release by Synapsins.
4 *J Neurosci* (2005) 25(10):2658-69. doi: 10.1523/jneurosci.4278-04.2005.
- 5 2. Valtorta F, Benfenati F, Greengard P. Structure and Function of the
6 Synapsins. *J Biol Chem* (1992) 267(11):7195-8.
- 7 3. Garcia CC, Blair HJ, Seager M, Coulthard A, Tennant S, Buddles M, et al.
8 Identification of a Mutation in Synapsin I, a Synaptic Vesicle Protein, in a Family with
9 Epilepsy. *J Med Genet* (2004) 41(3):183-6. doi: 10.1136/jmg.2003.013680.
- 10 4. Fassio A, Patry L, Congia S, Onofri F, Piton A, Gauthier J, et al. Syn1 Loss-of-
11 Function Mutations in Autism and Partial Epilepsy Cause Impaired Synaptic Function.
12 *Hum Mol Genet* (2011) 20(12):2297-307. Epub 20110325. doi: 10.1093/hmg/ddr122.
- 13 5. Giannandrea M, Guarnieri FC, Gehring NH, Monzani E, Benfenati F, Kulozik
14 AE, et al. Nonsense-Mediated Mrna Decay and Loss-of-Function of the Protein
15 Underlie the X-Linked Epilepsy Associated with the W356x Mutation in Synapsin I.
16 *PLoS One* (2013) 8(6):e67724. Epub 20130620. doi: 10.1371/journal.pone.0067724.
- 17 6. Kreye J, Wright SK, van Casteren A, Stöffler L, Machule ML, Reincke SM, et
18 al. Encephalitis Patient-Derived Monoclonal Gabaa Receptor Antibodies Cause
19 Epileptic Seizures. *J Exp Med* (2021) 218(11). Epub 20210921. doi:
20 10.1084/jem.20210012.
- 21 7. Noviello CM, Kreye J, Teng J, Prüss H, Hibbs RE. Structural Mechanisms of
22 Gaba(a) Receptor Autoimmune Encephalitis. *Cell* (2022) 185(14):2469-77.e13. doi:
23 10.1016/j.cell.2022.06.025.
- 24 8. Maljevic S, Møller RS, Reid CA, Pérez-Palma E, Lal D, May P, et al. Spectrum
25 of Gabaa Receptor Variants in Epilepsy. *Curr Opin Neurol* (2019) 32(2):183-90. doi:
26 10.1097/wco.0000000000000657.
- 27 9. Han VX, Patel S, Jones HF, Dale RC. Maternal Immune Activation and
28 Neuroinflammation in Human Neurodevelopmental Disorders. *Nature Reviews*
29 *Neurology* (2021) 17(9):564-79. doi: 10.1038/s41582-021-00530-8.
- 30 10. García-Serra A, Radosevic M, Pupak A, Brito V, Ríos J, Aguilar E, et al.
31 Placental Transfer of Nmdar Antibodies Causes Reversible Alterations in Mice.
32 *Neurol Neuroimmunol Neuroinflamm* (2021) 8(1). Epub 20201110. doi:
33 10.1212/nxi.0000000000000915.

- 1 11. Mader S, Brimberg L, Vo A, Strohl JJ, Crawford JM, Bonnin A, et al. In Utero
2 Exposure to Maternal Anti-Aquaporin-4 Antibodies Alters Brain Vasculature and
3 Neural Dynamics in Male Mouse Offspring. *Sci Transl Med* (2022)
4 14(641):eabe9726. Epub 20220420. doi: 10.1126/scitranslmed.abe9726.
- 5 12. Brimberg L, Mader S, Jeganathan V, Berlin R, Coleman TR, Gregersen PK, et
6 al. Caspr2-Reactive Antibody Cloned from a Mother of an Asd Child Mediates an
7 Asd-Like Phenotype in Mice. *Mol Psychiatry* (2016) 21(12):1663-71. Epub 20161004.
8 doi: 10.1038/mp.2016.165.
- 9 13. Jurek B, Chayka M, Kreye J, Lang K, Kraus L, Fidzinski P, et al. Human
10 Gestational N-Methyl-D-Aspartate Receptor Autoantibodies Impair Neonatal Murine
11 Brain Function. *Ann Neurol* (2019) 86(5):656-70. Epub 20190918. doi:
12 10.1002/ana.25552.
- 13 14. Höltje M, Mertens R, Schou MB, Saether SG, Kochova E, Jarius S, et al.
14 Synapsin-Antibodies in Psychiatric and Neurological Disorders: Prevalence and
15 Clinical Findings. *Brain Behav Immun* (2017) 66:125-34. Epub 20170718. doi:
16 10.1016/j.bbi.2017.07.011.
- 17 15. Piegras J, Höltje M, Otto C, Harms H, Satapathy A, Cesca F, et al. Intrathecal
18 Immunoglobulin a and G Antibodies to Synapsin in a Patient with Limbic Encephalitis.
19 *Neurology - Neuroimmunology Neuroinflammation* (2015) 2(6):e169. doi:
20 10.1212/nxi.0000000000000169.
- 21 16. Bünger I, Kreye J, Makridis K, Höltje M, Rasmussen HF, van Hoof S, et al.
22 Synapsin Autoantibodies During Pregnancy Are Associated with Fetal Abnormalities.
23 *medRxiv* (2022):2022.09.23.22280284. doi: 10.1101/2022.09.23.22280284.
- 24 17. Milovanovic D, Wu Y, Bian X, De Camilli P. A Liquid Phase of Synapsin and
25 Lipid Vesicles. *Science* (2018) 361(6402):604-7.
- 26 18. Prüss H. Autoantibodies in Neurological Disease. *Nature Reviews Immunology*
27 (2021) 21(12):798-813. doi: 10.1038/s41577-021-00543-w.
- 28 19. Rosahl TW, Spillane D, Missler M, Herz J, Selig DK, Wolff JR, et al. Essential
29 Functions of Synapsins I and II in Synaptic Vesicle Regulation. *Nature* (1995)
30 375(6531):488-93. doi: 10.1038/375488a0.
- 31 20. Rocchi A, Sacchetti S, De Fusco A, Giovedi S, Parisi B, Cesca F, et al.
32 Autoantibodies to Synapsin I Sequester Synapsin I and Alter Synaptic Function.
33 *Cell Death Dis* (2019) 10(11):864. Epub 20191114. doi: 10.1038/s41419-019-2106-z.

- 1 21. Coutinho E, Jacobson L, Pedersen MG, Benros ME, Nørgaard-Pedersen B,
2 Mortensen PB, et al. Caspr2 Autoantibodies Are Raised During Pregnancy in
3 Mothers of Children with Mental Retardation and Disorders of Psychological
4 Development but Not Autism. *J Neurol Neurosurg Psychiatry* (2017) 88(9):718-21.
5 Epub 20170601. doi: 10.1136/jnnp-2016-315251.
- 6 22. Duong SL, Prüss H. Molecular Disease Mechanisms of Human Antineuronal
7 Monoclonal Autoantibodies. *Trends Mol Med* (2022). Epub 20221021. doi:
8 10.1016/j.molmed.2022.09.011.
9
10

1 **Figures and Tables**

2 **Figure 1. Phenotype of children of mothers tested for SYN1 autoantibodies.**

3 Developmental delay in the domains speech and motor skills were the most common
4 findings, often associated with intellectual disability and epilepsy. Abbreviations: ID,
5 intellectual disability; ASD, autism-spectrum disorder.

6

7 **Figure 2. Detection of synapsin 1 (SYN1) autoantibodies. (A)** Examples of


8 immunofluorescence stainings, using human sera at a 1:300 dilution (green) with or
9 without binding to HEK cells overexpressing human SYN1b are shown in the top row
10 and bottom row. Using a commercial SYN1/2 antibody, protein expression is verified
11 (red). DAPI is used to stain the nuclei (blue). Scale bar: 20 μ m. **(B)** In 9.6% of
12 mothers SYN1 autoantibodies were detected using a CBA. **(C)** CBA and in-house
13 ELISA correlated weakly, with higher mean serum IgG levels in the CBA-positive
14 group. **(D)** Representative immunoblots of wild type (WT) and Syn1/2/3 triple KO
15 (TKO) mice cortex homogenates with a commercial synapsin 1/2 antibody as positive
16 control, and with sera (1:200 dilution) from a CBA-positive mother and a CBA-
17 negative control. Major bands at 80-90 kDa corresponding to the molecular weight of
18 synapsin 1a/1b and additional bands at 50-55 kDa that could represent the synapsin
19 2b isoform or breakdown products of synapsin 1 were detected in wild type but not in
20 TKO mouse tissue by both the commercial antibody and the serum of the CBA-
21 positive mother. Detection of GAPDH served as loading control. Abbreviations: HEK
22 human embryonic kidney; CBA, cell-based assay; ELISA, enzyme-linked
23 immunosorbent assay, WB, western blot.

24

25 **Figure 3. Clinical phenotype in patients of mothers with autoantibodies against**

26 **synapsin 1 (SYN1). (A, B)** Forest plot and bar chart showing the significantly

- 1 increased risk for intellectual disability and behavioral problems. Abbreviations: ID,
- 2 intellectual disability; ASD, autism-spectrum disorder.
- 3
- 4
- 5





A**B**

Table 1. Phenotype of patients with positive maternal synapsin I (SYN1) autoantibodies.

Abbreviations: ASD; autism-spectrum disorder; CM, Chiari malformation; DEE; Developmental and epileptic encephalopathy; DS, Dravet syndrome; HC; Hydrocephalus communicans; ID, intellectual disability; MAC, macrocephaly; MIC, microcephaly; MDLS, Miller-Dieker-Lissencephaly syndrome; NAD, no abnormality detected; n.p.; not performed; PCH, Pontocerebellar hypoplasia; SBH, subcortical band heterotopia; Genetic analysis: 1, chromosome analysis; 2, microarray-based comparative genomic hybridization (Array-CGH); 3, trio whole-exome analysis.

sex	age at test (range, years)	ID	cMRI	Epilepsy; seizures	Gene name	cDNA position	ACMG	NM number	OMIM	Speech	Motor skills	ASD	Behavior	MIC	MAC
m	6-10	+	CM	DEE; focal-onset atonic seizures	<i>AIFM1</i>	c.1465G>A	III	004208.3	300169	+	+	-	+	-	+
m	0-5	+	HC	DEE; generalized tonic-clonic seizures	1,2,3					+	+	-	+	-	+
m	0-5	+	n.p.	-	1,2					+	+	+	+	-	-
m	0-5	+	PCH	DEE; epileptic spasms	n.p.					+	+	-	+	+	-
m	0-5	-	peritrigonal, localized dysmyelination	-	<i>PTEN</i>	c.441A>T	IV	000314	601728	+	+	-	-	-	+
f	0-5	+	lissencephaly	DEE; focal onset clonic seizures without awareness	microdel. 17p13.3				247200, MDLS	+	+	-	-	-	-
m	0-5	+	delayed myelination	DEE; epileptic spasms	1,2,3				617057	+	+	+	-	+	-
m	0-5	+	NAD	focal onset seizures without awareness	n.p.					+	+	-	+	-	-
f	11-15	+	NAD	generalized tonic-clonic seizures	1,2					+	-	-	+	-	-
m	11-15	+	NAD	DEE; focal onset seizures without awareness	n.p.					+	+	-	+	+	-
m	6-10	+	NAD	-	<i>DPYD</i>	c.623G>T	III	000110	612779	+	+	+	+	-	-
m	0-5	+	NAD	-	n.p.					-	+	+	-	-	-
f	11-15	+	n.p.	-	<i>ANO5</i>	c.172C>T	IV	213599.2	608662	+	+	-	+	-	+
f	16-20	+	infra- and supratentorial atrophy	DEE; focal onset myoclonic seizures without awareness	<i>SCN1A</i>	c.3887T>C	III	001165963	182389, DS	+	+	-	-	+	-
m	0-5	+	n.p.	-	<i>DDB1</i>	c.637G>A	IV	001923	600045	+	+	-	-	-	-

m	0-5	+	n.p.	-	n.p.					+	+	-	+	-	-
f	0-5	+	SBH	focal onset myoclonic seizures without awareness	DCX	c.814C>T	V	000555	300121	+	+	-	-	+	-
m	0-5	+	n.p.	-	1					+	+	-	+	-	-
m	16-20	+	NAD	generalized tonic- clonic seizures	n.p.					-	-	-	+	+	-
m	6-10	-	NAD	epilepsy of unknow cause with tonic clonic seizures	n.p.					-	-	-	-	-	-